Nalbuphine hydrochloride ER is under clinical development by Trevi Therapeutics and currently in Phase III for Prurigo. According to GlobalData, Phase III drugs for Prurigo have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nalbuphine hydrochloride ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nalbuphine hydrochloride ER overview
Nalbuphine hydrochloride ER (T-111) is under development for the treatment of chronic pruritus in prurigo nodularis, pruritis in chronic liver disease, idiopathic pulmonary fibrosis, chronic cough in idiopathic pulmonary fibrosis patients. The drug candidate is administered through oral route as a tablet. The drug candidate is an extended release formulation of an existing compound nalbuphine hydrochloride. Nalbuphine is a phenanthrene derivative which targets opioid kappa and mu receptors and it was also under development for the treatment of atopic dermatitis. It was also under development for atopic dermatitis and uremic pruritus, levodopa-induced dyskinesia (LID) in Patients with Parkinson’s Disease. .
Trevi Therapeutics overview
Trevi Therapeutics is a clinical-stage biopharmaceutical company. It is developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi Therapeutics‘s Haduvio is a dual ?-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Trevi Therapeutics is headquartered in New Haven, Connecticut, the US.
For a complete picture of Nalbuphine hydrochloride ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
